Add dupilumab and mepolizumab to the toolbox for patients with chronic obstructive pulmonary disease and type 2 inflammation
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide. A subset of patients with COPD have pulmonary type 2 inflammation, creating an opportunity for a personalised medicine approach in these individuals. Dupilumab and mepolizumab are approved for the management of COPD with type 2 inflammation, while ensifentrine is approved for use in a broader COPD population. Several more biological therapies (including tezepemulab, tozorakimab and itepekimab) remain under investigation for COPD with type 2 inflammation.
Fields of Study & Subjects
Chronic Obstructive Pulmonary Disease (COPD) Research
Asthma and respiratory diseases
Inhalation and Respiratory Drug Delivery
Publication details
- Journal / source
- Drugs & Therapy Perspectives
- Volume
- 42
- Issue
- 1
- Pages
- 114–117
- Publication date
- 26 March 2026
- Language
- EN